Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) treatment in type 2 diabetes mellitus patients results in glucosuria, causing an energy loss, and triggers beneficial metabolic adaptations. It is so far unknown if SGLT2i exerts beneficial metabolic effects in prediabetic insulin resistant individuals, yet this is of interest since SGLT2is also reduce the risk for progression of heart failure and chronic kidney disease in patients without diabetes.

Source: Metabolism - Clinical and Experimental - December 30, 2022 Category: Biomedical Science Authors: Anna Veelen, Charlotte Andriessen, Yvo Op den Kamp, Edmundo Erazo-Tapia, Marlies de Ligt, Julian Mevenkamp, Johanna A. J örgensen, Esther Moonen-Kornips, Gert Schaart, Russell Esterline, Bas Havekes, Jan Oscarsson, Vera B. Schrauwen-Hinderling, Esther Ph Source Type: research